Search

Article Information


Proteolix: A "Me-Too" Success
Lasky, Larry , and Victoria Chang
55/2  (Winter 2013): 125-140

In an industry rife with failures, Proteolix, a biotechnology company, was a rare success. The Proteolix case provides a compelling example of a biotech company that has chosen a "me-too" strategy, a less risky strategy than the strategy of discovering a drug for a novel target. However, even me-too drug strategies in the biotech industry face an uphill battle. (Keywords: Biotechnology, Venture capital, Growth strategy)

 

California Management Review

Berkeley-Haas's Premier Management Journal

Published at the University of California for more than sixty years, California Management Review seeks to share knowledge that challenges convention and shows a better way of doing business.

Learn more
Follow Us